AKESO(09926) 21世纪经济报道·2025-05-14 02:19Core Viewpoint - The article emphasizes the importance of small and medium-sized enterprises (SMEs) in driving innovation in China, highlighting the role of specialized and innovative SMEs as leaders in this sector [1]. Group 1: Specialized and Innovative SMEs - Approximately 99% of enterprises in China are SMEs, with over 140,000 specialized and innovative SMEs cultivated, including more than 14,600 "little giant" enterprises [1]. - A meeting was held by the State Council Information Office featuring representatives from specialized and innovative SMEs to discuss their role in strengthening advanced manufacturing [1]. Group 2: Case Study - Guangdong Zhongshan Kangfang Biopharmaceutical Co., Ltd. - Summer Meng, a senior director at Guangdong Zhongshan Kangfang Biopharmaceutical Co., has been involved in clinical drug development for 12 years, focusing on confirming the efficacy and safety of new drugs [3]. - The company has developed 11 monoclonal antibody drugs, with over 16,000 patients participating in clinical trials, providing advanced treatment options for late-stage cancer patients [3]. - Four clinical projects managed by Summer Meng have been launched, including innovative drugs for gastric and cervical cancer, which have shown good clinical results and reduced medical costs [3]. Group 3: Policy Support and Industry Growth - The Guangdong government has identified biopharmaceuticals and health as one of its ten strategic pillar industries, implementing various supportive policies [4]. - In 2024, the biopharmaceutical and health industry cluster in Guangdong is expected to achieve approximately 448.66 billion yuan in revenue, with the pharmaceutical manufacturing sector generating 196.25 billion yuan [5]. - The government aims for the biopharmaceutical and health industry cluster to exceed one trillion yuan by 2027, with the scale of regulated pharmaceutical industry exceeding 500 billion yuan [5].